Retatrutide – Detailed Introduction & Benefits 

Retatrutide (LY3437943) is an investigational once‑weekly triple hormone receptor agonist developed by Eli Lilly. It is a 39‑amino‑acid synthetic peptide engineered to simultaneously activate three key metabolic receptors: GLP‑1, GIP, and glucagon (GCG). This “triple agonist” design builds on dual agonists like tirzepatide (Mounjaro/Zepbound) by adding glucagon activation for stronger weight loss and metabolic benefits. It is administered via subcutaneous injection and is currently in Phase 3 clinical trials for obesity, type 2 diabetes, and related conditions.

Core Mechanism of Action

Retatrutide’s power comes from balancing three complementary pathways:

1. GLP‑1 (Glucagon‑Like Peptide‑1)

   • Boosts glucose‑dependent insulin secretion (lowers blood sugar only when high).
   • Suppresses glucagon (prevents over‑production of sugar).
   • Slows gastric emptying → longer fullness, reduced food intake.
   • Acts on the brain to cut appetite and cravings.

2. GIP (Glucose‑Dependent Insulinotropic Polypeptide)

   • Amplifies insulin release, especially at normal/low glucose.
   • Enhances fat breakdown (lipolysis) and improves fat distribution.
   • Potentiates GLP‑1’s satiety effect for greater appetite control.

3. Glucagon (GCG) Receptor (Unique to Retatrutide)

   • Boosts energy expenditure (burns more calories at rest).
   • Stimulates liver fat oxidation → targets belly and liver fat.
   • Reduces liver fat buildup (improves NAFLD/MASH).
   • Balanced by GLP‑1/GIP so it does not raise blood sugar.

Net effect: Less hunger + more fat burn + better sugar control → unprecedented weight loss and metabolic improvement.

Key Benefits (Proven in Clinical Trials)

1. Powerful & Sustained Weight Loss

• Phase 2 (48 weeks): Up to 24.2% body weight loss (average ~20–24%) in obese adults without diabetes.
• Phase 3 (TRIUMPH‑4): Average 71.2 lbs (32.3 kg) weight loss at 12 mg; 28.7% weight loss in some cohorts.
• More effective than tirzepatide (~22.5% max) and semaglutide (~15–17%).
• Targets visceral (belly) fat and liver fat first.

2. Superior Glycemic Control (Type 2 Diabetes)

• Reduces HbA1c by up to 2.16% (36 weeks) – better than dulaglutide.
• Lowers fasting and post‑meal blood sugar; improves insulin sensitivity.
• Benefits prediabetes and metabolic syndrome.

3. Liver Health & Fatty Liver Improvement

• Cuts liver triglycerides and ALT (liver enzyme) levels.
• Reduces hepatic steatosis (fatty liver) and may help MASH/NAFLD.

4. Metabolic & Cardiovascular Protection

• Lowers waist circumference, BMI, triglycerides, and LDL (“bad” cholesterol).
• May reduce blood pressure and cardiovascular risk (under study).

5. Joint & Mobility Support

• Phase 3: Significant relief from knee osteoarthritis pain and improved function (linked to weight loss and reduced inflammation).

6. Safety & Tolerability

• Once‑weekly dosing improves adherence.
• Most common side effects: mild‑to‑moderate GI symptoms (nausea, diarrhea, constipation) – similar to other GLP‑1s.
• Low discontinuation rate (~12–18% at 9–12 mg).

Difference vs. Tirzepatide (Dual Agonist)

表格